Chromosomal Microarray (CMA) in Children with Psychiatric Disorders: Who to Test and What to Expect

August 9, 2018
The International Society of Psychiatric Genetics updated their Genetic Testing Statement in 2017 and recommended CMA testing for people with autism spectrum disorder (ASD), schizophrenia, or other psychiatric disorders, especially when accompanied by intellectual disability or other health concerns.

Brooke Spangler, MS, LCGC
Read more

Another great year contributing and sharing at ACMG 2018 in Charlotte, NC

April 26, 2018
It was great to see many of our existing Lineagen partners and meeting new ones at ACMG this year. We hope you enjoyed Lineagen’s happy hour event and learned more about our scientific contributions from our poster presentations. If you didn’t get a chance to join us in Charlotte, we have summarized the posters below. We will see you at the next scientific and clinical conference related to neurodevelopmental disorders!
Read more

Looking Outside of Guidelines for Genetic Testing

April 10, 2018
Since the publication of many of the guidelines regarding CMA testing, studies have been done which look at the diagnostic yield of CMA and role of copy number variants for a variety of clinical presentations. Examining these studies can provide insight into a broader spectrum of patients you see in your practice who could benefit from CMA testing.

Annie Baxter, MS, LCGC
Read more

Pharmacogenetics: Looking toward the future with personalized medicine

March 14, 2018
The concept of personalized medicine has been embraced by both providers and patients. In recent years, this has caused a boom in the utilization of pharmacogenetic testing.

Deanna Leingang, MS, LCGC
Read more

Genetic testing framework for neurodevelopmental disorders and epilepsy plus

March 6, 2018
Chromosomal Microarray with reflex to whole exome sequencing: beneficial genetic testing process for patients with neurodevelopmental disorders and patients with epilepsy plus.

Lauren Miller, MS, LCGC
Read more